CyBio Announces Sales and Earnings Guidance for the Current Financial Year 2011/2012
(Thomson Reuters ONE) -
CyBio AG /
CyBio Announces Sales and Earnings Guidance for the Current Financial Year
2011/2012
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
- Sales of EUR 11.0 million to EUR 11.5 million forecasted
- Operating earnings between EUR 1.0 million and EUR 1.2 million expected
Jena (Germany), April 26, 2012 - CyBio AG (Deutsche Börse: General Standard,
ISIN DE0005412308) expects consolidated sales of between EUR 11.0 million and
EUR 11.5 million for the current financial year 2011/2012. Thus, the provider of
solutions for liquid handling processes is unlikely to achieve its original
objective of a slight increase in sales in the current financial year. In the
last financial year, CyBio AG generated consolidated sales of EUR 11.7 million.
The Company continues to anticipate operating earnings within the scope of the
previous year's level - especially also due to cost reduction measures completed
as part of the restructuring program as well as thanks to significant
development support grants. In view of the low expected sales figures, the
Executive Management Board estimates that operating earnings (EBIT) are likely
to be between EUR 1.0 million and EUR 1.2 million (previous year: EUR 1.2
million) in 2011/2012. This was announced by CyBio AG today to mark its 13th
Annual General Meeting, which takes place tomorrow in Jena, Thuringia.
CEO of CyBio AG, Udo Werner, was critical of how the financial year had gone so
far: "We will need to intensify our efforts in marketing new product
developments so as to allow the Company to return to growth. As before, the
current focus must now primarily be on stabilizing our sales figures. At the
moment, in view of the fact that device sales have steadily dropped in the past
few years, this represents a major challenge. We can be cautiously satisfied
with our earnings. Here, we remain on course. We can build on a stable cost
situation and especially on research costs considerably reduced by development
support grants."
As part of the Company's restructuring, which was introduced in the second half
of 2009 with support from and on the initiative of the parent group Analytik
Jena, an extensive cost reduction program has been successfully completed. The
Group anticipates that the growth prospects developed as part of the
restructuring program will take at least another two years to realize.
The Company is set to announce the complete figures for the first six months of
2011/2012 on May 10, 2012.
Contact:
CyBio AG
Göschwitzer Str. 40
07745 Jena
Germany
Tel.: +49 (0) 3641.351 495
Fax: +49 (0) 3641.351 409
E-mail: irpr(at)cybio-ag.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: CyBio AG via Thomson Reuters ONE
[HUG#1606241]
Unternehmensinformation / Kurzprofil:
Datum: 26.04.2012 - 09:36 Uhr
Sprache: Deutsch
News-ID 139470
Anzahl Zeichen: 3529
contact information:
Town:
Jena
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 156 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CyBio Announces Sales and Earnings Guidance for the Current Financial Year 2011/2012"
steht unter der journalistisch-redaktionellen Verantwortung von
CyBio AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
